121800-M
Advanced Glycation Endproduct-BSA
AGE-BSA has been reported to induce apoptosis in cultured human umbilical vein endothelial cells and inhibit nitric oxide synthase activity in proximal tubular epithelial cells.
别名:
AGE-BSA
assay
≥95% (SDS-PAGE)
form
liquid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, avoid repeated freeze/thaw cycles
storage temp.
−70°C
Quality Level
General description
Prepared by reacting BSA with glycoaldehyde under sterile conditions. Glycated-BSA shows a 5,000 - 10,000% increase in fluorescence as compared to normal BSA (confirmed by fluorescence spectrophotometry, excitation/emission 370/440 nm). AGE-BSA has been reported to induce apoptosis in cultured human umbilical vein endothelial cells and inhibit nitric oxide synthase activity in proximal tubular epithelial cells. Advanced glycation end products and their receptors have been implicated in the pathogenesis of diabetes, induction of proinflammatory cytokines, and stimulation of smooth muscle proliferation, and fibronectin production.
Prepared by reacting bovine serum albumin (BSA) with glycoaldehyde under sterile conditions. Fluorescence of AGE-BSA is confirmed by fluorescence spectrophotometry, excitation/emission = 370/440 nm. Glycated BSA shows a 5000-10,000% increase in fluorescence compared to control BSA. AGE and their receptors have been implicated in the pathogenesis of diabetes, induction of pro-inflammatory cytokines, and stimulation of smooth muscle proliferation and fibronectin production. AGE-BSA has also been shown to induce apoptosis in cultured human umbilical vein endothelial cells (HUVEC) and inhibit nitric oxide synthase activity in proximal tubular epithelial cells of the kidney.
Physical form
In sterile-filtered PBS.
Other Notes
Okamoto, T., et al. 2002. Microvasc. Res.63, 186.
Ohgami, N., et al. 2001. J. Biol. Chem.276, 3195.
Wang, R., et al. 2001. J. Nippon Med. Sch.68, 472.
Sakata, N., et al. 2000. J. Atheroscler. Thromb.7, 169.
Verbeke, P., et al. 2000. Biochim. Biophys. Acta1502, 481.
Farboud, B., et al. 1999. Mol. Vis.5, 11.
Huang, J.-S., et al. 1999. Biochem. J.342, 231.
Min, C., et al. 1999. Diabetes Res. Clin. Pract.46, 197.
Neumann, A., et al. 1999. FEBS Lett.453, 283.
Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun.256, 549.
Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol.20, 83.
Ohgami, N., et al. 2001. J. Biol. Chem.276, 3195.
Wang, R., et al. 2001. J. Nippon Med. Sch.68, 472.
Sakata, N., et al. 2000. J. Atheroscler. Thromb.7, 169.
Verbeke, P., et al. 2000. Biochim. Biophys. Acta1502, 481.
Farboud, B., et al. 1999. Mol. Vis.5, 11.
Huang, J.-S., et al. 1999. Biochem. J.342, 231.
Min, C., et al. 1999. Diabetes Res. Clin. Pract.46, 197.
Neumann, A., et al. 1999. FEBS Lett.453, 283.
Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun.256, 549.
Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol.20, 83.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持